New drug cocktail aims to clear stubborn hand and foot pustules
NCT ID NCT07530367
First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times
Summary
This Phase 3 trial tests whether combining two drugs, tofacitinib and imatinib, can safely clear the painful pustules of palmoplantar pustulosis (PPP), a rare chronic skin disease on the palms and soles. About 135 adults with moderate-to-severe PPP will receive either the combo or a placebo for 16 weeks. The main goal is to see if at least 90% of the skin improves.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tofacitinib and imatinib
- What this could lead to
- If it works, this could provide the first approved treatment for palmoplantar pustulosis, significantly clearing skin lesions on hands and feet.
- What could go wrong
- This is an early-stage Phase 3 trial with only 135 participants. The combination therapy may cause side effects or fail to show better results than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PALMOPLANTAR PUSTULOSIS (PPP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.